Cannabis & Hemp Stocks Investment Tools – Schedule Demo Now!

Irvine, CA-based Cannabis Science, Inc. (OTC: CBIS), a firm developing cannabinoid-based medicines, confirmed receipt of a patent for compositions of cannabinol (CBN) to treat neurobehavioral disorders, sleep deprivation (Insomnia), anxiety disorders (ADHD), and Post-Traumatic Stress Disorders (PTSD).

The patent relates to a composition using cannabis extracts with Cannabinol (CBN) and other constituents—and a method for the extraction of plants. The compositions may be derived from Sativa, Indica, Ruderalis and/or other cannabis elements, and mixtures thereof.

Cannabis Science says it will “immediately go into commercial production in various markets” depending on regulatory environment and approvals. But it did not announce details of when or where.

CBIS is making various supplement combinations with CBN targeting Sleep Disorder and PTSD. It will license partners to develop them for mass distribution. It announced it has begun negotiations in the US and Canada and “expects a revenue stream” (it doesn’t say when) to help fuel the rest of its international drug development and economic development programs.

The market is potentially big. In U.S.A., over 50 million people have chronic sleep disorders, and 20 million people with occasional sleep disorders. Most use prescription drugs or Melatonin. Some FDA-approved treatments have side effects, such as daytime drowsiness, stomach pain, headache, breast enlargement in men, decreased sperm count in men, etc.

Cannabis Science, Inc. works to develop and commercialize new therapeutics to treat illnesses caused by infections as well as for age-related illness. Its initial focus is on cancers, HIV/AIDS, and neurological conditions. CBIS is proceeding with the R&D of its proprietary drugs as a part of this initial focus: CS-S/BCC-1, CS-TATI-1, and CS-NEURO-1, respectively.

Learn more about cannabis-based pharma companies in the Cannin Report. Sign up for Cannin Free Access and subscribe to the Cannin Chronicle. We’ll help you determine which cannabis companies to invest in.

Source: Cannabis Science press release